Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan

Reuters03-06

Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan

Hansoh Pharmaceutical Group Co. Ltd. reported that results from expansion cohorts of the ARTEMIS-001 first-in-human Phase 1a/1b trial (NCT05276609) of risvutatug rezetecan (HS-20093/GSK5764227), a B7-H3-targeted antibody-drug conjugate, in previously treated advanced solid tumors have been published in Cancer Cell. In lung cancer cohorts, confirmed objective response rates were 52.3% in extensive-stage small cell lung cancer (N=65) and 22.4% in non-small cell lung cancer (N=152), with median overall survival of 13.0 and 13.7 months, respectively; 8.0 mg/kg every three weeks was selected for Phase 3 development. The results have already been presented via publication, and the company said confirmatory Phase 3 studies in second-line SCLC are underway in China and globally, with additional pivotal lung cancer studies planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617038815?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617038815","market":"us","top_or_hot":-1,"title":"Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co. Ltd. reported that results from expansion cohorts of the ARTEMIS-001 first-in-human Phase 1a/1b trial (NCT05276609) of risvutatug rezetecan (HS-20093/GSK5764227), a B7-H3-targeted antibody-drug conjugate, in previously treated advanced solid tumors have been published in Cancer Cell. In lung cancer cohorts, confirmed objective response rates were 52.3% in extensive-stage small cell lung cancer (N=65) and 22.4% in non-small cell lung cancer (N=152), with median overall survival of 13.0 and 13.7 months, respectively; 8.0 mg/kg every three weeks was selected for Phase 3 development. The results have already been presented via publication, and the company said confirmatory Phase 3 studies in second-line SCLC are underway in China and globally, with additional pivotal lung cancer studies planned.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-06 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co. Ltd. reported that results from expansion cohorts of the ARTEMIS-001 first-in-human Phase 1a/1b trial (NCT05276609) of risvutatug rezetecan (HS-20093/GSK5764227), a B7-H3-targeted antibody-drug conjugate, in previously treated advanced solid tumors have been published in Cancer Cell. In lung cancer cohorts, confirmed objective response rates were 52.3% in extensive-stage small cell lung cancer (N=65) and 22.4% in non-small cell lung cancer (N=152), with median overall survival of 13.0 and 13.7 months, respectively; 8.0 mg/kg every three weeks was selected for Phase 3 development. The results have already been presented via publication, and the company said confirmatory Phase 3 studies in second-line SCLC are underway in China and globally, with additional pivotal lung cancer studies planned.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL41Z7dS:1","article_id":"2617038815","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617038815","pubTimestamp":1772758808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co. Ltd. reported that results from expansion cohorts of the ARTEMIS-001 first-in-human Phase 1a/1b trial  of risvutatug rezetecan , a B7-H3-targeted antibody-drug conjugate, in previously treated advanced solid tumors have been published in Cancer Cell. In lung cancer cohorts, confirmed objective response rates were 52.3% in extensive-stage small cell lung cancer  and 22.4% in non-small cell lung cancer , with median overall survival of 13.0 and 13.7 months, respectively; 8.0 mg/kg every three weeks was selected for Phase 3 development. The results have already been presented via publication, and the company said confirmatory Phase 3 studies in second-line SCLC are underway in China and globally, with additional pivotal lung cancer studies planned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","03692":"翰森制药","BK1589":"北水核心资产","BK1583":"高瓴概念"},"translate_title":"Cancer Cell公布豪森Risvutatug Rezetecan的1期肺癌结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Cancer Cell Publishes Phase 1 Lung Cancer Results for Hansoh’s Risvutatug Rezetecan\n    \n\n        Hansoh Pharmaceutical Group Co. Ltd. reported that results from expansion cohorts of the ARTEMIS-001 first-in-human Phase 1a/1b trial (NCT05276609) of risvutatug rezetecan (HS-20093/GSK5764227), a B7-H3-targeted antibody-drug conjugate, in previously treated advanced solid tumors have been published in Cancer Cell. In lung cancer cohorts, confirmed objective response rates were 52.3% in extensive-stage small cell lung cancer (N=65) and 22.4% in non-small cell lung cancer (N=152), with median overall survival of 13.0 and 13.7 months, respectively; 8.0 mg/kg every three weeks was selected for Phase 3 development. The results have already been presented via publication, and the company said confirmatory Phase 3 studies in second-line SCLC are underway in China and globally, with additional pivotal lung cancer studies planned.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617038815","isCrawlerRequest":true}